BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27699663)

  • 1. Impact of point mutation P29S in RAC1 on tumorigenesis.
    Rajendran V; Gopalakrishnan C; Purohit R
    Tumour Biol; 2016 Nov; 37(11):15293-15304. PubMed ID: 27699663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamic simulation reveals damaging impact of RAC1 F28L mutation in the switch I region.
    Kumar A; Rajendran V; Sethumadhavan R; Purohit R
    PLoS One; 2013; 8(10):e77453. PubMed ID: 24146998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic Differences of Activation of Rac1
    Senyuz S; Jang H; Nussinov R; Keskin O; Gursoy A
    J Phys Chem B; 2021 Apr; 125(15):3790-3802. PubMed ID: 33848152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAC1
    Lionarons DA; Hancock DC; Rana S; East P; Moore C; Murillo MM; Carvalho J; Spencer-Dene B; Herbert E; Stamp G; Damry D; Calado DP; Rosewell I; Fritsch R; Neubig RR; Molina-Arcas M; Downward J
    Cancer Cell; 2019 Jul; 36(1):68-83.e9. PubMed ID: 31257073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAC1P29S is a spontaneously activating cancer-associated GTPase.
    Davis MJ; Ha BH; Holman EC; Halaban R; Schlessinger J; Boggon TJ
    Proc Natl Acad Sci U S A; 2013 Jan; 110(3):912-7. PubMed ID: 23284172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAC1 and melanoma.
    Halaban R
    Clin Ther; 2015 Mar; 37(3):682-5. PubMed ID: 25465943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recurrent somatic activating RAC1 mutations in melanoma].
    Dereure O
    Ann Dermatol Venereol; 2012 Nov; 139(11):785-6. PubMed ID: 23199784
    [No Abstract]   [Full Text] [Related]  

  • 8. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
    Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
    Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational landscape alternations promote oncogenic activities of Ras-related C3 botulinum toxin substrate 1 as revealed by NMR.
    Toyama Y; Kontani K; Katada T; Shimada I
    Sci Adv; 2019 Mar; 5(3):eaav8945. PubMed ID: 30891502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
    Mar VJ; Wong SQ; Logan A; Nguyen T; Cebon J; Kelly JW; Wolfe R; Dobrovic A; McLean C; McArthur GA
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1117-25. PubMed ID: 25043693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAC1 P29S regulates PD-L1 expression in melanoma.
    Vu HL; Rosenbaum S; Purwin TJ; Davies MA; Aplin AE
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):590-8. PubMed ID: 26176707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
    Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
    Oncogene; 2024 Mar; 43(10):729-743. PubMed ID: 38243078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1
    Tomino T; Tajiri H; Tatsuguchi T; Shirai T; Oisaki K; Matsunaga S; Sanematsu F; Sakata D; Yoshizumi T; Maehara Y; Kanai M; Cote JF; Fukui Y; Uruno T
    Biochem Biophys Res Commun; 2018 Feb; 497(1):298-304. PubMed ID: 29432733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased conformational stability in the oncogenic N92I mutant of Ras-related C3 botulinum toxin substrate 1.
    Toyama Y; Kontani K; Katada T; Shimada I
    Sci Adv; 2019 Aug; 5(8):eaax1595. PubMed ID: 31457101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.
    Foth M; Parkman G; Battistone B; McMahon M
    Pigment Cell Melanoma Res; 2020 Sep; 33(5):719-730. PubMed ID: 32406574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting effector pathways in RAC1
    Uribe-Alvarez C; Guerrero-Rodríguez SL; Rhodes J; Cannon A; Chernoff J; Araiza-Olivera D
    Small GTPases; 2021 Jul; 12(4):273-281. PubMed ID: 32043900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of surface plasmon resonance (SPR) and fluorescence resonance energy transfer (FRET) to monitor the interaction of the plant G-proteins Ms-Rac1 and Ms-Rac4 with GTP.
    Brecht M; Sewald K; Schiene K; Keen G; Fricke M; Sauer M; Niehaus K
    J Biotechnol; 2004 Aug; 112(1-2):151-64. PubMed ID: 15288950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Dendritic Actin Network Formation in Extended Lamellipodia Drives Proliferation in Growth-Challenged Rac1
    Mohan AS; Dean KM; Isogai T; Kasitinon SY; Murali VS; Roudot P; Groisman A; Reed DK; Welf ES; Han SJ; Noh J; Danuser G
    Dev Cell; 2019 May; 49(3):444-460.e9. PubMed ID: 31063759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAC1 as a Therapeutic Target in Malignant Melanoma.
    Cannon AC; Uribe-Alvarez C; Chernoff J
    Trends Cancer; 2020 Jun; 6(6):478-488. PubMed ID: 32460002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique vulnerability of
    Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
    bioRxiv; 2023 Jun; ():. PubMed ID: 37425776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.